Pioglitazone enhances brain mitochondrial biogenesis and phase II detoxification capacity in neonatal rats with 6-OHDA-induced unilateral striatal lesions

The psychostimulant methylphenidate (MPH) is the first-line pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), but has numerous adverse side effects. The PPARγ receptor agonist pioglitazone (PIO) is known to improve mitochondrial bioenergetics and antioxidant capacity, bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Vázquez-González, Daniela, Corona, Juan Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416244/
https://www.ncbi.nlm.nih.gov/pubmed/37575308
http://dx.doi.org/10.3389/fnins.2023.1186520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416244/
https://www.ncbi.nlm.nih.gov/pubmed/37575308
http://dx.doi.org/10.3389/fnins.2023.1186520

Ejemplares similares